Lower threshold to NFκB activity sensitizes murine β-cells to streptozotocin

Clyde J Wright1, Sarah McKenna1, Robyn De Dios1

  • 1Section of Neonatology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.

Insights

Streptozotocin (STZ) alone does not activate NFκB in beta cells. However, reducing IκBβ or adding TNFα sensitizes cells to STZ, increasing diabetes risk. Stabilizing NFκB inhibitors may prevent beta-cell injury.

Area of Science:

  • Endocrinology
  • Immunology
  • Molecular Biology

Background:

  • The role of beta-cell response to injury in diabetes development is crucial.
  • Nuclear Factor kappa B (NFκB) signaling is implicated in cellular stress responses.

Purpose of the Study:

  • To investigate the role of NFκB activation in streptozotocin (STZ)-induced beta-cell injury.
  • To determine how modulating IκBβ levels affects STZ-induced NFκB activation and beta-cell death.

Main Methods:

  • MIN6 cells and IκBβ knockout (IκBβ-/-) mice were treated with STZ, TNFα, and/or IκBβ siRNA.
  • NFκB activation was assessed by gene expression (Nos2, Cxcl10), protein localization (p65, p50), and inhibitor levels (IκBβ, IκBα).
  • Cell viability was measured using trypan blue exclusion, and diabetes onset in mice was monitored.

Main Results:

  • STZ alone (2 mM) did not induce NFκB activation in MIN6 cells.
  • Knocking down IκBβ with siRNA or co-incubation with TNFα sensitized MIN6 cells to STZ, leading to increased NFκB target gene expression and cell death.
  • IκBβ-/- mice exhibited a higher incidence of STZ-induced hyperglycemia and diabetes compared to wild-type controls.

Conclusions:

  • STZ-induced beta-cell injury and diabetes development are dependent on the sensitization of the NFκB pathway.
  • Lowering the threshold for NFκB activation enhances STZ's diabetogenic effects.
  • Stabilizing NFκB inhibitory proteins may offer a therapeutic strategy to prevent beta-cell injury and diabetes.